title: Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
abstract: OBJECTIVE
  We analyzed iron deficiency and the therapeutic response following intravenous ferric carboxymaltose in a large single-center inflammatory bowel disease (IBD) cohort.
  
  
  METHODS
  250 IBD patients were retrospectively analyzed for iron deficiency and iron deficiency anemia. A subgroup was analyzed regarding efficacy and side effects of iron supplementation with ferric carboxymaltose.
  
  
  RESULTS
  In the cohort (n = 250), 54.4% of the patients had serum iron levels ≤60 μg/dl, 81.2% had ferritin ≤100 ng/ml, and 25.6% had hemoglobin (Hb) of ≤12 g/dl (females) or ≤13 g/dl (males). In the treatment subcohort (n = 80), 83.1% of the patients had iron ≤60 μg/dl, 90.4% had ferritin ≤100 ng/ml, and 66.7% had Hb ≤12/13 g/dl before ferric carboxymaltose treatment. After a median dose of 500 mg ferric carboxymaltose, 74.7% of the patients reached iron >60 μg/dl, 61.6% had ferritin >100 ng/ml, and 90.7% reached Hb >12/13 g/dl at follow-up (p < 0.0001 for all parameters vs. pretreatment values). The most frequent adverse event was a transient increase of liver enzymes with male gender as risk factor (p = 0.008, OR 8.62, 95% CI 1.74-41.66).
  
  
  CONCLUSIONS
  Iron deficiency and anemia are frequent in IBD patients. Treatment with ferric carboxymaltose is efficious, safe and well tolerated in iron-deficient IBD patients.
authors.affiliation: Department of Medicine II, University Hospital Munich-Grosshadern, Munich, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Beigel
authors.forename: Beate
authors.initials: B
authors.lastname: Löhr
authors.forename: Rüdiger P
authors.initials: RP
authors.lastname: Laubender
authors.forename: Cornelia
authors.initials: C
authors.lastname: Tillack
authors.forename: Fabian
authors.initials: F
authors.lastname: Schnitzler
authors.forename: Simone
authors.initials: S
authors.lastname: Breiteneicher
authors.forename: Maria
authors.initials: M
authors.lastname: Weidinger
authors.forename: Burkhard
authors.initials: B
authors.lastname: Göke
authors.forename: Julia
authors.initials: J
authors.lastname: Seiderer
authors.forename: Thomas
authors.initials: T
authors.lastname: Ochsenkühn
authors.forename: Stephan
authors.initials: S
authors.lastname: Brand
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D015331:Cohort Studies; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy*; D007262:Infusions, Intravenous; D007501:Iron / Q000097:blood; D008297:Male; D008320:Maltose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005290:Ferric Compounds; D006454:Hemoglobins; C522335:ferric carboxymaltose; D008320:Maltose; D005293:Ferritins; D007501:Iron